when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog
drugs
Humira

drug

adalimumab

Marketedupdated 3mo ago

by $ABBV AbbVie Inc.

Approved

annual revenue · 2024–2024peak $9.0B

community read0 votes

🐶 often sniffed alongside

top 8

tagApproval432 co-mentions · 155 sources
drugHUMIRA359 co-mentions · 156 sources
drugAMJEVITA168 co-mentions · 94 sources
drugABRILADA156 co-mentions · 88 sources
drugYUSIMRY152 co-mentions · 86 sources
company$ABBVAbbVie Inc.122 co-mentions · 61 sources
drugYUFLYMA28 co-mentions · 14 sources
drugHADLIMA26 co-mentions · 13 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 20 investigational indications.

indications

investigational

IBD (Crohn's + UC)Rheumatoid Arthritis

all catalysts(61)

approval · 61

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

$ABBV261.83-1.56%

HUMIRA (ADALIMUMAB) — FDA approval

view all 61 catalysts →

Trials studying adalimumab

phase3Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritiscompletedn=487
phase3A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumabrecruitingn=40
phase1A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjectscompletedn=444
phase4A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasisrecruitingn=30
phase4A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Diseaserecruitingn=100
phase3A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitisactive not recruitingn=30
phase3A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasiscompletedn=478
phase4A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasisnot yet recruitingn=30

more trials →

News(5)

MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
fiercebiotech · 11d ago
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
biospace · 21d ago
cAMPfield lands $180M to build gut disease drug
The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
biopharma_dive · 2mo ago
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important clues.
biopharma_dive · 2mo ago
Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs
“We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.
stat · 3mo ago

brand

Humira

generic

adalimumab

MOA

12.1 Mechanism of Action Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased concentrations of TNF are also found in psoriasis plaques. In Ps, treatment with HUMIRA may reduce the epidermal thickness and infiltration of inflammatory cells. The relationship between these pharmacodynamic activities and the mechanism(s) by which HUMIRA exerts its clinical effects is unknown. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the concentrations of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC 50 of 1-2 X 10 -10 M).

indication

Intermediate Uveitis

phase

marketed

approved

2002-12-31

Data sources

openFDA · ClinicalTrials.gov

last refreshed 21m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?